Ocrevus, a disease modifying therapy which is available for both relapsing forms of MS and early primary progressive MS has up until now been available only in intravenous (IV) form, which is administered in hospital infusion units. Unfortunately, long waiting lists for hospital infusion appointments have caused significant delays for some people who could benefit from starting or continuing this medication.
The availability of the subcutaneous version, which can be administered more quickly and may be accessed in a wider range of clinical settings, offers the potential for faster access, reduced hospital capacity pressures and greater flexibility for people living with MS and the healthcare teams who support them.
We hope this development will help address the current bottlenecks in IV treatment pathways and ensure that more people who may benefit from this treatment can access it without unnecessary delays. As support services are put in place, the subcutaneous form will be rolled out in clinical settings around the country over the coming months.
Speaking about the decision, MS Ireland CEO Ava Battles said:
“We are delighted to see the HSE take this important step. We know from speaking with people living with MS and their clinicians that long waiting times for IV infusions have been a major source of stress and concern. The subcutaneous form offers a more accessible option and should help ensure timely treatment for those who need it."